肺癌分子检测在发展中国家的应用

doi:10.3760/cma.j.issn.1673-422X.2014.01.015

摘要/Abstract

摘要： 非小细胞肺癌的个体化治疗时代已经到来，至少对于腺癌患者，基因检测是决定日常临床治疗的一部分。在发展中国家基因检测受到了多方面的限制，如质控、花费/成本、推广。由于发展中国家的国情差异，其所制定的策略也是不同的。发展中国家应以其新兴的科技能力创新和验证新型生物标志物和诊断试剂盒的使用，并收集分子流行病学资料，以利于全球肺癌患者获得更好的治疗。

关键词: 癌, 非小细胞肺, 基因, 发展中国家

Abstract: The era of personalized medicine of nonsmall cell lung cancer has arrived. Gene detecrion is part of the daily clinical decision, at least for patients with adenocarcinoma. Access to those tests is still very limited in the developing world: quality control, reimbursement/cost and widespread access. Because of the differences in the national conditions of developing countries, strategies certainly vary from country to country. Molecular epidemiology data generated by developing countries, as well as the use of their emerging scientific and technologic capacities to generate and validate novel biomarkers and diagnostic kits, will certainly contribute to better treatment of patients with lung cancer worldwide.

Key words: Carcinoma, non-small-cell lung, Genes, Developing countries

贾友超, 商琰红, 臧爱民. 肺癌分子检测在发展中国家的应用[J]. 国际肿瘤学杂志, 2014, 41(1): 47-49.

Jia Youchao, Shang Yanhong, Zang Aimin. Applications of molecular detection of lung cancer in developing countries[J]. Journal of International Oncology, 2014, 41(1): 47-49.

参考文献

［1］ Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012［J］. CA Cancer J Clin, 2012, 62:1029. ［2］ McCloskey P, Balduyck B, Van Schil PE, et al. Radical treatment of nonsmall cell lung cancer during the last 5 years［J］. Eur J Cancer, 2013, 49(7):15551564. ［3］ Hennon MW, Yendamuri S. Advances in lung cancer surgery［J］. J Carcinog, 2012, 11:21. ［4］ National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lungcancer mortality with lowdose computed tomographic screening［J］. N Engl J Med, 2011, 365(5):395409. ［5］ Seo JS, Ju YS, Lee WC, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma［J］. Genome Res, 2012, 22(11):21092119. ［6］ Azzoli CG, Baker S Jr, Temin S, et al. American society of clinical oncology clinical practice guideline update on chemotherapy for stage Ⅳ nonsmallcell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2010, 13(3):171189. ［7］ Wolff AC, Hammond ME, Schwartz JN, et al. American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer［J］. J Clin Oncol, 2007, 25(1):118145. ［8］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J cancer, 2010, 127(12):28932917. ［9］ Atherly AJ, Camidge DR. The costeffectiveness of screening lung cancer patients for targeted drug sensitivity markers［J］. Br J Cancer, 2012, 106(6):11001116. ［10］ Couraud S, Zalcman G, Milleron B, et al. Lung cancer in never smokersa review［J］. Eur J Cancer, 2012, 48(9):12991311. ［11］周航, 梅同华, 赵麟丰, 等. 肺癌分子靶向治疗的现状与进展. 国际肿瘤学杂志, 2007, 34(7):493496. ［12］ Galanter JM, FernandezLopez JC, Gignoux CR, et al. Development of a panel of genomewide ancestry informative markers to study admixture throughout the Americas［J］. PLoS Genet, 2012, 8(3):e1002554. ［13］ Reich D, Patterson N, Campbell D, et al. Reconstructing Native American population history［J］. Nature, 2012, 488(7411):370374. ［14］ Bacchi CE, Ciol H, Queiroga EM, et al. Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients［J］. Clinics (Sao Paulo), 2012, 67(5):419424. ［15］ Pena SD, Di Pietro G, FuchshuberMoraes M, et al. The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected［J］. PLoS One, 2011, 6(2):e17063. ［16］ Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers［J］. Nature, 2012 489(7417):519525.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[5]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[6]	顾芳萌, 徐晨阳, 雷大鹏. 人工智能辅助电子喉镜检查在喉癌及喉癌前病变诊治中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(5): 303-307.
[7]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[8]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[9]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[10]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[11]	胡婷婷, 王越华. 电子鼻与线虫鼻——新型早期癌症筛查工具[J]. 国际肿瘤学杂志, 2024, 51(4): 223-226.
[12]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[13]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[14]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[15]	钱晓涛, 石子宜, 胡格. Ⅲ~ⅣA期食管鳞状细胞癌根治性放化疗后行免疫检查点抑制剂维持治疗的真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(3): 151-156.